Target intelligence / Profile preview

Actin-associated protein FAM107A (FAM107A)

Target: FAM107A
Molecular classification: Actin-associated/cytoskeleton-binding protein, Other (not a classical receptor, enzyme, or ion channel, but a stress-responsive protein influencing actin and microtubule dynamics)

Overview

Actin-associated protein FAM107A is a stress-inducible actin-binding protein with a conserved N-terminal DUF1151 domain, involved in the organization of the cytoskeleton through its ability to bind, stabilize, and bundle F-actin. It plays critical roles in cell cycle regulation, neuronal cell migration, and synaptic function, and acts as a candidate tumor suppressor downregulated in various cancers, likely through promoter hypermethylation and other epigenetic mechanisms. In the nervous system, FAM107A is highly expressed, essential for neural cell survival, migration, and synaptic plasticity, and may be implicated in neuropsychiatric disorders. Although no approved therapeutics directly target FAM107A, its roles in disease and cellular stress response highlight its potential as a diagnostic and prognostic biomarker

Other names: FAM107ADRR1TU3AFamily with sequence similarity 107 member ADown-regulated in renal cell carcinoma 1Protein TU3AActin-associated protein FAM107A

Mechanism of action

N/A (no approved drugs or drugs in clinical study directly targeting FAM107A)

Biological functions

Cytoskeleton organizationActin filament polymerization/bundlingCell cycle regulation (negative regulation of G1/S transition)Focal adhesion modulationRegulation of cell migration (promotes/controls migration in neural and glial cells)Apoptosis induction (tumor suppressor activity)Neural synaptic and cognitive functions

Disease associations

Cancer (candidate tumor suppressor; downregulated in renal cell carcinoma, breast, thyroid, prostate, colon, astrocytoma; data suggest complex roles in tumor proliferation and invasion)Neurodegenerative disease/psychiatric disorders (expressed highly in brain, implicated in schizophrenia, bipolar disorder, and possibly other CNS disorders)Other (Robinow Syndrome, Autosomal Dominant 1; neuroblastoma association)

Safety considerations

None specifically reported, as FAM107A is not a direct therapeutic target; however, its general tumor suppressor activity means overexpression or restoration therapy might have risk of affecting normal cell homeostasis

Interacting drugs

None identified to date in public datasets. No direct small molecule or biologic drugs are reported that target FAM107A

Biomarkers

Loss or decrease of FAM107A expression may serve as a biomarker for certain cancers (renal cell carcinoma, breast cancer, colon cancer, thyroid cancer, prostate cancer, astrocytoma)Possible biomarker for neuropsychiatric disorders (schizophrenia, bipolar disorder; based on increased mRNA expression)

Beyond the preview

Go deeper on Actin-associated protein FAM107A (FAM107A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actin-associated protein FAM107A (FAM107A).

Explore the full profile